Further, and perhaps more importantly, information about the particular assay used by a given lab is often difficult to find: the type of assay (for example,
“chemiluminescent immunoassay”) is often listed in a lab’s on-line catalog, but none of the faxed reports of urine NTX results identified whether the Vitros ECi or Osteomark assay had been used. Of the faxed reports of serum BAP results, only the Esoterix and LabCorp this website reports indicated the assay employed, and even then, LabCorp referred to an outdated form of the Ostase test. The findings of the present study support the call for urgent improvement in analytical precision for these two biochemical markers of bone turnover. Laboratory performance data should be made widely available to clinicians, institutions, and payers, and proficiency testing and standardized guidelines should be strengthened to improve marker reproducibility at those labs currently performing poorly. Acknowledgments The authors thank James Dyes, Heather Finlay, Timothy Hamill, MD, and Pitavastatin research buy Steve Miller, MD, PhD for their assistance with specimen processing and storage. Funding source Support for this investigation came from the Alliance for Better Bone Health. Conflicts of
interest Dr. Bauer is a consultant for Tethys Bioscience and Roche Diagnostics. The other authors declare that they have no conflicts of interest or disclosures. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References 1. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone Interleukin-2 receptor turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700CrossRefPubMed 2. Ravn P,
Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368CrossRefPubMed 3. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056CrossRefPubMed 4. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351CrossRefPubMed 5.